UNSPSC 51422123: Prednisone intensol

This classification denotes a therapeutic glucocorticoid with the molecular formula C21H26O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VB0R961HZT, chemically known as 17,21-dihydroxypregna-1,4-diene-3,11,20-trione, but more generally known as prednisone intensol, which bears US NIH Compound Identifier 5865. European Medicines Agency schedules prednisone intensol or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10020MIG.

Most nations, for tariff purposes, schedule prednisone intensol under HS 29372100. SMILES: C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C.

UNSPSC 51422123 Prednisone Intensol is a Commodity code that nominally describes a specific corticosteroid medication, but recent state and local opportunities tagged under this code show a substantial mismatch: the two most recent solicitations concern naloxone and drug deactivation systems procurement, and a direct-to-manufacturer prescription program initiative, neither of which aligns with prednisone intensol as a pharmaceutical product. The code appears to see minimal relevant activity in current state and local procurement channels, and the tagging discrepancy suggests potential classification drift or miscoding in the source databases that states and localities use to publish opportunities.

The one traceable opportunity with geographic placement is Seminole County, Florida, which posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through an IFB with a response deadline of July 26, 2023—a date that has already passed relative to the posting date, indicating a data consistency issue in the source. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, soliciting vendor capabilities for a therapeutic pharmacy initiative direct-to-manufacturer prescription program, but this is exploratory market intelligence rather than a formal procurement with binding terms. Neither opportunity directly engages prednisone intensol procurement. Firms should verify current UNSPSC tagging practices with state and local procurement offices before committing resources under this code, as the nominal scope and actual buying activity show insufficient alignment to support reliable opportunity forecasting.